UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: September 24, 2018
(Date of earliest event reported)
ANAPTYSBIO, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 001-37985 | 20-3828755 | |
| (Commission File Number) |
(IRS Employer Identification No.) |
| 10421 Pacific Center Court, Suite 200 San Diego, CA |
92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(858) 362-6295
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD.
On September 24, 2018, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing top line proof of concept data from an interim analysis of AnaptysBio’s ongoing etokimab Phase 2a trial in severe eosinophilic asthma. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
On September 24, 2018, AnaptysBio held an investor conference call. A copy of the slides presented during the investor conference call are furnished as Exhibit 99.2 to this report and incorporated herein by reference.
The information furnished with this report, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit |
Description of Exhibit | |
| 99.1 | Press release dated September 24, 2018. | |
| 99.2 | Slides presented by AnaptysBio on September 24, 2018. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AnaptysBio, Inc. | ||||||
| Date: September 24, 2018 | By: | /s/ Dominic Piscitelli | ||||
| Name: | Dominic Piscitelli | |||||
| Title: | Chief Financial Officer | |||||
Exhibit 99.1
AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma
| • | Lung function improvement occurred rapidly following a single dose of etokimab, with an 8 percent increase in FEV1 over placebo at Day 2 |
| • | FEV1 improvement was sustained throughout the interim analysis period, with an 11 percent increase over placebo at Day 64 |
| • | Blood eosinophil reduction was consistent with lung function improvement, with 31 percent and 46 percent reduction over placebo at Day 2 and Day 64, respectively |
| • | Management to host conference call today at 8:30 a.m. EDT |
SAN DIEGO, Sept. 24, 2018 — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topline proof-of-concept data for etokimab, its investigational anti-IL-33 therapeutic antibody, in an ongoing single dose Phase 2a clinical trial in adult patients with severe eosinophilic asthma. Patients administered with etokimab rapidly improved their Forced Exhaled Volume In One Second (FEV1), which is a measure of lung function, with an 8 percent FEV1 improvement over placebo at Day 2. FEV1 improvement was sustained through Day 64, with an 11 percent increase over placebo. Blood eosinophil reduction was sustained through the interim analysis period, with a 31 percent reduction at Day 2 and a 46 percent reduction at Day 64 over placebo, which was consistent with FEV1 improvement observed in this trial. Etokimab was generally well tolerated in all patients and no serious adverse events were reported as of this interim analysis.
“Eosinophilic asthma is a debilitating medical condition that results from severe inflammation and airway obstruction,” said Dr. Ian Pavord, professor of Respiratory Medicine at University of Oxford and principal investigator of the Phase 2a trial. “The benefit observed in this trial after a single dose of etokimab demonstrates the potential for IL-33 inhibition in treating severe eosinophilic asthma. I look forward to the continued advancement of etokimab in subsequent clinical trials for patients suffering from this chronic life-long disease.”
Phase 2a Trial Design
This Phase 2a proof-of-concept trial enrolled 25 adult severe eosinophilic asthma patients, who were randomized between a single 300mg intravenous dose of etokimab or placebo upon enrollment (Day 1) at six sites located in the United States and the United Kingdom. Upon screening, which occurred seven to 14 days prior to enrollment, patients were required to have a blood eosinophil count of at least 300 per microliter, confirmed clinical diagnosis of severe asthma according to the Global Initiative for Asthma (GINA) 2016, pre-bronchodilator FEV1 of less than 80 percent of predicted and at least one asthma exacerbation within the past 12 months requiring use of rescue medication. Patients were required to be stably maintained on high-dose inhaled corticosteroids (ICS) and long-acting beta-2-agonists (LABA) for at least three months prior to screening and were required to continue ICS/LABA therapy during the course of this trial. Baseline clinical assessments were conducted for each patient on Day 1 prior to etokimab or placebo dose, and patients completed follow-up clinical assessments on Days 2, 8, 22, 36 and
64 as of this interim analysis. The last follow-up visit for each patient will occur on Day 127 post-dose.
Interim Analysis
Key data and observations as of this interim analysis indicate the following:
| • | Baseline parameters of etokimab-dosed patients (n=12) were 545 blood eosinophils per microliter, 2.5 liters FEV1 and 65 percent predicted FEV1, while placebo-dosed patients (n=13) had 705 blood eosinophils per microliter, 2.5 liters FEV1 and 66 percent predicted FEV1. Nine of 12 (75%) etokimab-dosed patients were male with an average age of 41, while nine of 13 (69%) placebo-dosed patients were male with an average age of 36. |
| • | Etokimab was generally well-tolerated by all patients and no serious adverse events were reported as of this interim analysis. No treatment-emergent adverse events were deemed to be etokimab-related, and the most frequent treatment-emergent adverse events reported were single occurrences of moderate strep throat in two etokimab-dosed patients and single occurrences of mild vomiting in two placebo-dosed patients. No exacerbations or rescue therapy usage has been reported as of the interim analysis. |
“We are thrilled to have demonstrated proof-of-concept in this single dose Phase 2a trial and look forward to advancing the development of etokimab for patients suffering from eosinophilic asthma,” said Hamza Suria, president and chief executive officer of AnaptysBio. “Genotypic studies have validated the key role played by IL-33 in asthma, and we believe etokimab’s upstream mechanism has the potential for a broad therapeutic benefit across multiple atopic disorders.”
This Phase 2a trial is currently ongoing and the company plans to report full data from this trial at a medical conference in 2019 following trial completion.
AnaptysBio plans to continue development of etokimab in eosinophilic asthma with a multi-dose Phase 2b randomized, double-blinded, placebo-controlled trial, which is expected to be initiated in 2019.
Conference Call & Webcast Information
The AnaptysBio management team will host a conference call and live webcast on Monday Sept. 24, 2018, at 8:30 a.m. EDT to discuss the information in this press release.
Dial-in: (833) 696-8361 (domestic) or (430) 775-1625 (international)
Conference ID: 5798647
The live webcast and accompanying slides can be accessed under the investor relations section of AnaptysBio’s website at www.anaptysbio.com. A replay of the conference call will be archived under the investor relations section of the AnaptysBio website for 30 days shortly after the call.
About Etokimab
Etokimab, previously referred to as ANB020, is an antibody that potently binds and inhibits the activity of interleukin-33 (IL-33), a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, which AnaptysBio believes is broadly applicable to the treatment of atopic inflammatory disorders, such as moderate-to-severe atopic dermatitis, severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and potentially other allergic conditions. Following completion of a healthy volunteer Phase 1 trial of etokimab, AnaptysBio continued clinical development of etokimab into a Phase 2a trial for moderate-to-severe adult atopic dermatitis and a placebo-controlled Phase 2a trial in severe adult eosinophilic asthma patients. AnaptysBio is enrolling its ATLAS trial, a randomized, double-blinded, placebo-controlled multi-dose Phase 2b clinical trial of etokimab in 300 moderate-to-severe adult atopic dermatitis patients where data is anticipated in the second half of 2019. The company also plans to initiate its ECLIPSE trial, a randomized, double-blinded, placebo-controlled Phase 2 trial of etokimab in approximately 100 adult patients with CRSwNP by the end of 2018 with data anticipated in the second half of 2019. AnaptysBio also plans to initiate a randomized, double-blinded, placebo-controlled, multi-dose Phase 2b trial of etokimab in patients with eosinophilic asthma in 2019.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (etokimab, previously referred to as ANB020) for the treatment of moderate-to-severe atopic dermatitis, severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP); its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP), previously referred to as palmo-plantar pustular psoriasis; and
novel anti-inflammatory checkpoint receptor modulator antibodies for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene.
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including etokimab’s Phase 2b clinical trial in moderate-to-severe adult atopic dermatitis patients and etokimab’s Phase 2 clinical trial in adult patients with CRSwNP; our design of and our ability to launch a Phase 2 clinical trial of etokimab in adults patients with CRSwNP and a Phase 2b clinical trial of etokimab in eosinophilic asthma; and statements by AnaptysBio’s president and chief executive officer. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
###
Contacts:
Monique Allaire
THRUST Investor Relations
617.895.9511
monique@thrustir.com
Chelcie Lister
THRUST Investor Relations
910.777.3049
chelcie@thrustir.com
 Nasdaq:
ANAB Etokimab (Anti-IL-33) Program
Phase 2a Eosinophilic Asthma Clinical Trial
Interim Data Update September 24 th 2018 Exhibit 99.2 |
 Safe
Harbor Statement 2
This presentation and the accompanying oral presentation contain
“forward-looking” statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from
our clinical trials, including etokimab’s Phase 2b clinical
trial in moderate-to-severe adult atopic dermatitis patients, etokimab’s Phase 2 clinical trial in adult chronic rhinosinusitis with nasal polyps patients and ANB019’s Phase 2 trials in GPP and PPP patients; the design of and our ability
to launch a Phase 2 clinical trial of etokimab in adult chronic
rhinosinusitis with nasal polyps patients, a Phase 2b clinical trial of etokimab in severe eosinophilic asthma patients and a Phase 2 clinical trial of ANB019 in PPP patients; the timing of detailed data presentation of
etokimab’s Phase 2a clinical trial in severe adult
eosinophilic asthma patients; the timing of an IND filing for an anti-inflammatory checkpoint modulator; and the success of our partnership with TESARO and Celgene. Statements including words such as “plan,” “continue,”
“expect,” or “ongoing” and statements in the
future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those
expressed or implied by such forward-looking statements.
Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and
uncertainties related to the company’s ability to advance
its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve
development goals, the company’s ability to protect
intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC). These forward-looking statements speak only as of
the date of this presentation, and the company undertakes no
obligation to revise or update any forward-looking statements to reflect events or circumstances after the date
hereof. Certain information contained in this presentation may be derived from information provided by industry sources. The Company
believes such information is accurate and that the sources from
which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of, and has not independently verified, such information. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be
construed as an endorsement of such products. |
 Etokimab Eosinophilic Asthma Phase 2a: Top-line data today ANB019 Generalized Pustular Psoriasis Phase 2: Top-line data in early 2019 Etokimab Atopic Dermatitis Phase 2b: Top-line data in H2 2019 Etokimab Chronic Rhinosinusitis With Nasal Polyps Phase 2: Top-line data in H2 2019 ANB019 Palmoplantar Pustulosis Phase 2: Top-line data in H2 2019 AnaptysBio: Clinical-Stage Antibody Development Company Focused on Novel Antibody Medicines for Severe Inflammatory Diseases 3 TESARO Celgene Rapid Antibody Generation Platform Technology ~2.5 years Antibody Discovery Preclinical & Translational IND or Equivalent Filing Antibody Medicines For Severe Diseases Wholly-Owned Anti-Inflammatory Pipeline Etokimab (ANB020, Anti-IL-33) Atopic Dermatitis, Eosinophilic Asthma & Chronic Rhinosinusitis with Nasal Polyps
ANB019 (Anti-IL-36R)
Generalized Pustular Psoriasis & Palmoplantar Pustulosis
Checkpoint Modulator Inflammatory Diseases 4 Additional Efficacy Readouts Anticipated By End 2019 Validating Product Partnerships Generated ~$75MM* * As of June 30 th 2018 |
 Wholly-Owned and Partnered Product Pipeline
6 AnaptysBio-Generated Antibodies Advanced to Clinic Since Q1 2016
All programs generated internally using AnaptysBio’s proprietary antibody generation
platform technology 4 |
 IL-33 acts as a gatekeeper of allergic response with demonstrated activity in the initiation (activation of ILC2 cells) , propagation (activation of allergen-specific T and B cells) and amplification (degranulation of mast cells and basophils) . 5 Etokimab: First-in-Class Anti-IL-33 Antibody Broadly Applicable to Atopic Diseases • IL-33 is an upstream driver of atopic disease – Human genetics validate key role of IL-33 in atopic dermatitis and asthma – Pro-inflammatory cytokine released upon allergen contact with epithelium – Activates downstream release of IL-4, IL-5 and IL-13 – Modulates IgE-mediated mast cell and basophil degranulation • Etokimab is a potentially first-in- class anti-IL-33 cytokine antibody – Phase I healthy volunteer trial completed without dose-limiting toxicities – AnaptysBio pursuing development in moderate-to-severe atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps 1. Cayrol et al. Curr Opin Immunol (2014) 31:31 2. Peine et al. Trends Immunol (2016) 37(5):321 3. Saluja et al. Clin Transl Allergy (2015) 5:33 2 1 3 |
 Eosinophilic Asthma Focus on Severe Patients Inadequately Controlled With ICS/LABA 6 • Eosinophilic asthma is a debilitating, chronic atopic disease - Decreased lung function associated with poor quality-of-life and exacerbations - Often concomitant with other atopic diseases, such as chronic rhinosinusitis with nasal polyps and atopic dermatitis • Significant unmet medical need - ~1.1 million US adults diagnosed with severe asthma and inadequately controlled with inhaled corticosteroids and long-acting-beta-agonists (ICS/LABA) - Approximately 50% estimated to be eosinophilic asthmatics |
 Etokimab
Clinical Trials 7
Subjects Trial Trial Design Key Clinical Endpoint(s) Timing Healthy Volunteers Phase 1 n=96, SAD and MAD cohorts, IV and SC dosing, randomized, placebo-controlled Safety, PK and PD Top-line data announced October 2016 Detailed data presented at AAD and AAAAI 2017 Moderate-to-Severe Adult Atopic Dermatitis Phase 2a n=12, single IV dose Eczema Area & Severity Index (EASI) Top-line data announced October 2017 Detailed data presented at AAD and EAACI 2018 ATLAS Phase 2b n=300, SC multi-dose, randomized, placebo-controlled EASI Anticipate top-line data in H2 2019 Moderate-to-Severe Baseline Adult Peanut Allergy Phase 2a n=20, single IV dose, randomized, placebo-controlled Oral Food Challenge (OFC) Top-line data announced March 2018 De-prioritized for commercial reasons Eosinophilic Asthma Phase 2a n=25, single IV dose, randomized, placebo-controlled Forced Expiratory Volume in 1 Second (FEV1) Top-line data announced today Detailed data presentation anticipated in 2019 Phase 2b Undisclosed Undisclosed Anticipate initiation in 2019 Adult Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) ECLIPSE Phase 2 n=100, SC multi-dose, randomized, placebo-controlled Nasal Polyps Score (NPS); Sino- Nasal Outcome Test-22 (SNOT-22) Anticipate top-line data in H2 2019 |
 8 Etokimab Eosinophilic Asthma Phase 2a Trial Single Dose of Etokimab or Placebo Administered on Day 1 Patient Population ClinicalTrials.gov: NCT03469934 Etokimab 300mg IV Single Dose + High Dose ICS/LABA n=12 Placebo Single Dose + High Dose ICS/LABA n=13 Adults with severe asthma (according to GINA 2016) Pre-bronchodilator FEV1 <80% of predicted Blood eosinophils 300 cells/microliter 1 asthma exacerbation in past year requiring rescue medication Stably maintained on ICS/LABA dose for at least 3 months prior to screening
Efficacy: % change in FEV1 relative to baseline
Biomarker: change in blood eosinophil levels
Safety Key Endpoints |
 9 Key Baseline Parameters Average Baseline Parameters of Enrolled Patients (Day 1 Pre-Dose) Etokimab Arm Placebo Arm n 12 13 Blood Eosinophils per microliter 545 705 FEV1 (Liters) 2.5 2.5 % Predicted FEV1 65% 66% Age (years) 41 36 Male % 75% (9 of 12) 69% (9 of 13) |
 % FEV1
Improvement Relative to Baseline After Single Dose Rapid and Sustained FEV1
Improvement Post-Etokimab Administration 10
Timepoint Etokimab Placebo Net Day 1 (Baseline) 0% 0% 0% Day 2 12% 4% 8% Day 8 9% 5% 4% Day 22 16% 8% 8% Day 36 14% 8% 6% Day 64 15% 4% 11% |
 Blood
Eosinophil Reduction Relative to Baseline After Single Dose Correlates with
FEV1 Improvement and Consistent With Phase 2a Atopic Dermatitis Trial
11 Timepoint Etokimab Placebo Net Day 1 (Baseline) 0% 0% 0% Day 2 -22% 9% -31% Day 8 -34% -15% -19% Day 22 -30% -10% -20% Day 36 -43% 1% -44% Day 64 -40% 6% -46% |
 12 Eosinophilic Asthma Phase 2a Day 64 Interim Analysis Supports Advancement of Etokimab Into Phase 2b Eosinophilic Asthma Trial Interim Analysis Summary • Etokimab demonstrated proof-of-concept in eosinophilic asthma • Single dose of etokimab resulted in rapid and sustained improvement in FEV1 over placebo
• Blood eosinophil biomarker reduction correlated with FEV1 improvement and is consistent
with prior etokimab Phase 2a atopic dermatitis trial
• Etokimab was generally well-tolerated and no serious adverse events reported
- No treatment-emergent adverse events were deemed to be etokimab-related
- The most frequent treatment-emergent adverse events reported were single occurrences of moderate strep throat in two etokimab-dosed patients and single
occurrences of mild vomiting in two placebo-dosed patients
- No exacerbations or rescue therapy usage was reported Next Steps • Complete ongoing Phase 2a trial and present detailed data at a medical conference in 2019
• Initiate Phase 2b randomized, double-blinded, placebo-controlled, multi-dose trial of
etokimab in eosinophilic asthma during 2019 |
 Anticipated Milestones 4 Additional Efficacy Readouts Anticipated By End 2019 Program Milestone Timing Etokimab (anti-IL-33) Moderate-to-Severe Adult Atopic Dermatitis Phase 2a Trial Top-line data announced October 2017 Detailed data presented at AAD and EAACI 2018 ATLAS: Moderate-to-Severe Adult Atopic Dermatitis Phase 2b Trial Initiated H1 2018 Top-line data anticipated in H2 2019 Severe Adult Eosinophilic Asthma Phase 2a Trial Top-line data presented today Detailed data to be presented in 2019 Eosinophilic Asthma Phase 2b Trial To be initiated in 2019 ECLIPSE: Adult Chronic Rhinosinusitis with Nasal Polyps Phase 2 Trial To be initiated by end 2018 Top-line data anticipated in H2 2019 ANB019 (anti-IL-36R) Healthy Volunteer Top-line Phase I Trial Top-line data announced November 2017 Detailed data presented at EAACI 2018 GALLOP: GPP Phase 2 Trial Initiated H1 2018 Top-line data anticipated in early 2019 POPLAR: PPP Phase 2 Trial Initiated H2 2018 Top-line data anticipated in H2 2019 Approximately $300MM in cash, cash equivalents and investments as of June 30 2018
13 th |
 AnaptysBio: Clinical-Stage Antibody Development Company
Focused on Novel Antibody Medicines for Severe Inflammatory Diseases
14 TESARO Celgene Rapid Antibody Generation Platform Technology ~2.5 years Antibody Discovery Preclinical & Translational IND or Equivalent Filing Antibody Medicines For Severe Diseases Wholly-Owned Anti-Inflammatory Pipeline Etokimab (ANB020, Anti-IL-33) Atopic Dermatitis, Eosinophilic Asthma & Chronic Rhinosinusitis with Nasal Polyps
ANB019 (Anti-IL-36R)
Generalized Pustular Psoriasis & Palmoplantar Pustulosis
Checkpoint Modulator Inflammatory Diseases 4 Additional Efficacy Readouts Anticipated By End 2019 Validating Product Partnerships Generated ~$75MM* Etokimab Eosinophilic Asthma Phase 2a: Top-line data today ANB019 Generalized Pustular Psoriasis Phase 2: Top-line data in early 2019 Etokimab Atopic Dermatitis Phase 2b: Top-line data in H2 2019 Etokimab Chronic Rhinosinusitis With Nasal Polyps Phase 2: Top- line data in H2 2019 ANB019 Palmoplantar Pustulosis Phase 2: Top-line data in H2 2019 * As of June 30
2018 th |
 |